AMDI
Autonomous Medical Devices Incorporated develops point-of-care diagnostic systems, like its Fast PCR system that provides results in under 10 minutes.
Secondary Market Price
How AMDI Measures Up
To help you manage your AMDI equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
TBD
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of AMDI's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future AMDI Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for AMDI's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Autonomous Medical Devices Incorporated (AMDI) is a company focused on developing rapid molecular diagnostic technologies. Its current efforts are centered on the AMDI Fast PCR system, a platform designed to deliver results for key pathogens in less than 10 minutes. This system is intended for use in urgent care centers, primary care offices, retail clinics, and office laboratories. In addition to its main platform, the company provides protein engineering solutions and has products for research use only, such as Autolab™ HBH. Specific details regarding the company's founding and early history are not provided in available information.
AMDI's forward-looking strategy is heavily focused on regulatory approval and market entry for its Fast PCR system. A recent key development for the company was its 510(k) and CLIA Waiver dual submission to the U.S. Food and Drug Administration (FDA). Following potential clearance, the company plans to launch the system commercially to its identified customer segments. AMDI has also indicated an interest in forming partnerships, though no specific collaborations have been announced.
- As a federal agency, the National Institute of Biomedical Imaging and Bioengineering is publicly funded and does not have private investors.
- The available information does not specify the founders of AMDI.
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is AMDI worth joining?
Deciding whether to join any private company like AMDI requires a careful evaluation of your offer, particularly the equity compensation component. Platforms like Prospect can help you model the potential future value of your stock options to make a more informed decision.
What should I do with my AMDI stock?
Managing stock in a private company involves complex decisions around exercising options, tax implications, and timing potential sales. Using a specialized tool can help you create a personalized strategy to optimize the value of your equity.
Can you sell AMDI stock?
As AMDI is a private company, you generally cannot sell shares on a public stock exchange and must wait for a liquidity event like an IPO or acquisition. Some private companies occasionally permit sales through secondary markets or tender offers, and tools exist to help you navigate these opportunities.
How can I find the value of my AMDI stock?
The value of stock in a private company isn't publicly available and is typically based on internal 409A valuations or the price set during its most recent funding round. To better understand its potential future worth, equity management platforms use predictive models to forecast a range of possible outcomes.
What is AMDI's equity worth?
The total equity valuation of a private company like AMDI is determined by investors during funding rounds and is not public information. Your personal equity's value depends on that valuation, the total number of shares, and your specific grant details.
What is AMDI's stock ticker symbol?
Private companies like AMDI are not traded on public stock exchanges, so they do not have a stock ticker symbol. A ticker symbol is only assigned when a company completes an Initial Public Offering (IPO) and lists on an exchange like the NYSE or NASDAQ.
Can I buy or sell AMDI stock?
Buying stock in a private company is typically restricted to accredited investors during specific funding rounds, while selling is limited to company-approved liquidity events. Employees looking to understand their options for selling can use financial modeling tools to prepare for events like tender offers.
What is the criteria to buy or invest in AMDI stock?
Investing in a private startup is generally limited to venture capital firms and accredited investors who are invited to participate in private funding rounds. For employees, the primary way to acquire equity is through compensation in the form of stock options or RSUs, rather than direct investment.
